Citius Pharma (CTXR) Shareholder Letter | Year Ahead Roadmap.
2021 and 2020 Milestones In Plain Sight.
Locked and Loaded for most of 2020 - many major milestone events lie around the corner for Citius...
Citius Pharma (CTXR) Video Presentation.
Chairman Leonard Mazur Discusses:
Mino-Lok Treatment for Infected Catheters.
Novellus Stem Cell Treatment for CoronaVirus and Acute Respiratory Distress. (This is not a vaccine folks, it...
Immunomedics (IMMU) $3.00 to $88, Up 29-fold, Our Second Best Idea Ever.
Interesting Charts From the Day we Discovered it.
Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into...
American BriVision’s (ABVC) Clinical Study Sparks Interest From Potential Partners.
Is Wall Street Missing American Brivision's Full Clinical Safety and Efficacy Study? We Think it has.
Potential Partners are Now Able to Examine Vitargus® the...
There’s Simply No Loyalty Anymore.
TODAY'S LETTER
Frontier Bio (FBIO) $3.90. We Have Another Double! American BriVision (ABVC) $4.00. Wait, What? Yet Another Double.Aphex BioCleanse (SNST) $1.80. Wait, What? Seeking...
And We Have Another Double. Frontier Bio (FBIO) Crosses $4.00.
Sometimes we Can't Beleive Our Luck Over the Last Couple Years. But There You Have it, at Least we Know It's Luck!
While we are...
American BriVision’s (ABVC) Novel Polygala Plant Extract, for the Treatment of Clinical Depression.
American BriVision Announces New Patent Filed for Treatment of Major Depressive Disorder.
Phase II clinical study completed at Stanford University and five major medical centers...
Investors Bet $8 Million on Citius Pharma (CTXR) $1.10, Succeeding in FDA Trials!
Great headline, right?
The actual headline was: Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million
In reality, we don't know if the...
American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.
American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD.
Last patient last visit (LPLV) marked the...
Latest article
Jeffrey Gundlach: Reckoning is Coming.
Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm.
On 11 November 2020, Gundlach remarked in an interview with...
Who’s the Next Eric Sprott?
To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...
Perpetua (PPTA) Raises $300 Million.
Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...
